Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBIT (2016 - 2025)

Historic EBIT for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $5.3 million.

  • Lifecore Biomedical, Inc. \De\'s EBIT rose 14788.27% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$17.2 million, marking a year-over-year decrease of 9501.3%. This contributed to the annual value of -$17.2 million for FY2025, which is 9499.1% down from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s EBIT stood at $5.3 million, which was up 14788.27% from -$9.0 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s EBIT's 5-year high stood at $5.3 million during Q2 2025, with a 5-year trough of -$11.6 million in Q3 2024.
  • Moreover, its 5-year median value for EBIT was -$2.9 million (2022), whereas its average is -$3.3 million.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s EBIT surged by 17394.21% in 2021 and then tumbled by 1330273.97% in 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s EBIT (Quarter) stood at $3.7 million in 2021, then plummeted by 245.04% to -$5.4 million in 2022, then soared by 72.29% to -$1.5 million in 2023, then tumbled by 32.1% to -$2.0 million in 2024, then soared by 371.92% to $5.3 million in 2025.
  • Its EBIT stands at $5.3 million for Q2 2025, versus -$9.0 million for Q1 2025 and -$2.0 million for Q4 2024.